- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01399528
A Pharmacogenomic Exploration of Lacosamide Response
This is an observational study exploring the genetics of lacosamide response. The study will last 3 years and has been divided in to three stages; 1) recruitment, 2) observational phase, 3) genotyping and analysis. Patients initiating lacosamide are recruited and their baseline seizure frequency is assessed retrospectively. Patients are then monitored for 18 months with an assessment (via interview and where possible seizure diaries) of seizure frequency and other treatment related phenotypes every 3 months. The recruitment period will span months 1-12, the observational period will span months 1-30 and analysis of data will be conducted between months 30-36 (see Figure 2 below). Target sample size is 610.
Primary objective: To determine the clinical relevance of genetic variation in predicting lacosamide responsive and non-responsive patients.
Secondary objectives: To determine the clinical relevance of genetic variation in predicting:
- Optimal dose of lacosamide
- Adverse drug reactions to lacosamide
Studieoversikt
Status
Forhold
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: Gianpiero Cavalleri, PhD
- Telefonnummer: +353 1 4022146
- E-post: gcavalleri@rcsi.ie
Studiesteder
-
-
-
Brussels, Belgia
- Rekruttering
- Hospital Erasme
-
Ta kontakt med:
- Chantal Depondt
-
-
-
-
North Carolina
-
Durham, North Carolina, Forente stater
- Rekruttering
- Duke Medical Centre
-
Ta kontakt med:
- Saraubh Sinha
-
-
-
-
-
Dublin, Irland, D4
- Rekruttering
- Beaumont Hospital
-
Ta kontakt med:
- Gianpiero Cavalleri, PhD
- Telefonnummer: +353 1 4022146
- E-post: gcavalleri@rcsi.ie
-
Hovedetterforsker:
- Norman Delanty
-
Dublin, Irland
- Rekruttering
- St.James Hospital
-
Ta kontakt med:
- Colin Doherty
-
-
-
-
-
London, Storbritannia
- Rekruttering
- The Institute of Neurology
-
Ta kontakt med:
- Sanjay Sisodiya
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Diagnosed with partial onset seizures (simple and/or complex) with or without secondary generalization (based on 1981 ILAE seizure classification scheme)
- Over 18 and under 65 years of age at date of recruitment in to the study
- Currently undergoing pharmacological treatment for refractory partial epilepsy ('refractory' here refers to patients who continue to have seizures despite treatment (current) with two or more appropriate anti-epileptic drugs at appropriate doses)
- Deemed suitable for treatment with lacosamide (following drug guidelines)
Exclusion Criteria:
- Patients experiencing seizure type other than partial onset seizures (with/without secondary generalisation)
- Patients with a history of chronic alcohol or drug abuse within previous 3 years.
- Non refractory epilepsy patients
- Patients suffering any other clinically significant disease e.g. cancers, progressive neurological disorder, heart failure, respiratory failure etc
- Patients who are pregnant or who are intending on getting pregnant within the period of the trial.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Beaumont Hospital, Dublin, Ireland
|
St. James' Hospital, Dublin, Ireland
|
Hôpital Erasme, Brussels, Belgium
|
Duke Medical Centre, North Carolina, USA
|
The Institute of Neurology/University College London, UK
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Seizure frequency
Tidsramme: Recorded daily by participant. Passed on to study researchers every 3 months for an 18 month period
|
We will record seizure type and frequency.
Seizure types will follow definitions as provided by the International League Against Epilepsy.
Seizure frequency will be as recorded by the participant in a seizure diary.
|
Recorded daily by participant. Passed on to study researchers every 3 months for an 18 month period
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Maintenance dose
Tidsramme: Recorded every three months for an 18 month period
|
Maintenance dose will be defined as the tolerated daily dose required by the patient for seizure control.
|
Recorded every three months for an 18 month period
|
Adverse drug reactions
Tidsramme: Recorded as reaction arise during the 18 month study period
|
We will record any adverse reactions recorded by the study participant, including for example (but not limited to): dizziness, ataxia, vomiting, diplopia, nausea, vertigo, and vision blurred.
|
Recorded as reaction arise during the 18 month study period
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Norman Delanty, MB FRCPI, Beaumont Hospital and Royal College of Surgeons in Ireland
- Hovedetterforsker: Gianpiero L Cavalleri, PhD, Royal College of Surgeons in Ireland
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- RCSI_LCM
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .